Mads Nikolaj Behrndt-Eriksen
CFO & GMMr. Mads Nikolaj Behrndt-Eriksen, M.Sc is Chief Financial Officer at Hemab ApS since September 2021 and serves as General Manager since 2023. Mr. Behrndt-Eriksen has been the Chief Financial Officer and General Manager at Hemab Therapeutics Holdings, Inc. since September 2021. He has extensive experience in the international capital markets as well as within strategy and business development. He joined Hemab from PwC, where he was a Partner at PwC’s Corporate Finance practice. At PwC, he led and executed private and public company financings and M&A transactions. He earned an MSc in Finance & Strategic Management from the Copenhagen Business School, Denmark and a B.Sc. in Economics and Business Administration Management from the Copenhagen Business School.
Positions
- Company NameHemab Therapeutics Holdings, Inc.Stock CodeCOAGPositionCFO & GMColleagues
- BSBenny SorensenPresident, CEO & Director
- JMJohn Michael MaraganoreIndependent Chairman
- CECatherine Eilleen MadiganChief Medical Officer
- ASAnanthram Sreenivasa MurthyChief Operating Officer
- KWKaren WeisbachChief People & Culture Officer
- LCLinda Cathavina BainIndependent Director
- AKAkshay Krishnadas VaishnawIndependent Director
- KWKeli WalbertDirector
